Tempo Raises $220M in New Capital to Enhance AI & 3D Sensor Technology

Tempo the first home fitness system that uses advanced 3D sensors and AI to analyze users’ motion to provide a personal training experience—today announced $220 million in new funding.

Tempo notes the Series C round was led by SoftBank Vision Fund 2* with participation from new investor Steadfast Capital Ventures, and returning investors DCM, General Catalyst, Norwest Venture Partners, and Bling Capital. This brings Tempo’s funding to date to nearly $300 million.

Tempo will allocate the new funding toward the continued enhancement of its AI and 3D sensor technology to further expand its cutting-edge, real-time form feedback and personal guidance for users. The company also recently announced vast expansions across its hardware, software, and content offerings to best supplement the training experience and continue to deliver a full, at-home gym and personal trainer experience.

“Tempo was launched on the premise that the most advanced and versatile technology can unlock human potential by redefining the personal training experience. Today, our AI uses 3D sensors and is trained on over 5M workouts over 40K hours to give our users the most effective and personalized workouts possible,” said Moawia Eldeeb, Co-Founder and CEO of Tempo. “This new funding allows Tempo to further develop its AI to expand our class categories and content offerings.”

With its unique offering for at-home fitness, Tempo has gained significant momentum since launching in 2020. In the past year alone, Tempo saw its sales increase by 10 times and has seen 0% subscription cancellation.

“The fitness landscape has transformed dramatically as more consumers seek home fitness solutions. By providing personalized AI generated feedback through its computer vision technology, Tempo delivers the experience of working out with a personal trainer to consumers in their homes,” said Jeff Housenbold, Managing Partner, SoftBank Investment Advisers. “We’re excited to partner with Moawia and the Tempo team to support their ambition to help people progress in their fitness journeys at home.”

As the only complete yet incomparably compact and connected home training solution on the market, the Tempo Studio combines the hands-on guidance of a personal trainer, the motivation of a group fitness class, and premium design-forward equipment. After more than six years of developing Tempo’s flagship product, the company remains dedicated to providing the most efficient and personalized fitness experience to its community.

SourceTempo

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”